Hemoglobin metabolites mimic benzodiazepines and are possible mediators of hepatic encephalopathy

Blood

Volumn 102, Issue 4, 2003, Pages 1525-1528

  Ruscito, Brian J ^b   Harrison, Neil L ^a  

^a Weill Cornell Graduate School of Biomedical Sciences   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE; DIAZEPAM; HEMIN; HEMOGLOBIN; PROTOPORPHYRIN; ZOLPIDEM;

ARTICLE; BRAIN NERVE CELL; DRUG EFFECT; EMBRYO; HEPATIC ENCEPHALOPATHY; HUMAN; HUMAN CELL; METABOLITE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION;

EID: 0042738825     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-03-0739     Document Type: Article

References (31)

1. Anderson RN. National Vital Statistics Reports. Vol 50. No. 16. Hyattsville, MD: National Center for Health Statistics; 2002.
2. Goulenok C, Bernard B, Cadranel JF, et al. Flumazenil vs placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Ailment Pharmacol Ther. 2002;16:361-372.
3. Meier R, Gyr G. Treatment of hepatic encephalopathy (HE) with the benzodiazepine antagonist flumazenil: a pilot study. Eur J Anaesthesiol Suppl. 1988;2:139-146.
4. Tallman JF, Thomas JW, Gallager DW. GABAergic modulation of benzodiazepine binding site sensitivity. Nature. 1978;27;383-385.
5. A receptor benzodiazepine binding site. CNS Drug Rev. 1999;5:125-144.
6. Basile AS, Harrison PM, Hughes RD, et al. Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy. Hepatology. 1994;19:112-121.
7. Olasmaa M, Rothstein JD, Guidotti A, et al. Endogenous benzodiazepine receptor ligands in human and animal hepatic encephalopathy. J Neurochem. 1990;55:2015-2023.
8. Rothstein JD, Olasmaa M. Endogenous GABAergic modulators in the pathogenesis of hepatic encephalopathy. Neurochem Res. 1990;15:193-197.
9. Basile AS, Panell L, Jaouni T, et al. Brain concentrations of benzodiazepines are elevated in an animal model of hepatic encephalopathy. Proc Natl Acad Sci U S A. 1990;87:5263-5267.
10. Mullen KD, Jones EA. Natural benzodiazepines and hepatic encephalopathy. Semin Liver Dis. 1996;16:225-264.
11. Gammal SH, Basile AS, Geller D, Skolnick P, Jones EA. Reversal of the behavioral and electrophysiological abnormalities of an animal model of hepatic encephalopathy by benzodiazepine receptor ligands. Hepatology. 1990;11:371-378.
12. Basile AS, Hughes RD, Harrison PM, et al. Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure. N Engl J Med. 1991;325:473-478.
13. Verma A, Nye JS, Snyder SH. Porphyrins are endogenous ligands for the mitochondrial (peripheral-type) benzodiazepine receptor. Proc Natl Acad Sci U S A. 1987;84:2256-2260.
14. Gross U, Hoffmann GF, Doss MO. Erythropoietic and hepatic porphyrias. J Inherit Metab Dis. 2000;23:641-661.
15. Harrison NL. On the presynaptic action of baclofen at inhibitory synapses between cultured rat hippocampal neurons. J Physiol. 1990;422:433-446.
16. Koltchine VV, Finn SE, Jenkins A, Nikolaeva N, Lin A, Harrison NL. Agonist gating and isoflourane potentiation in the human gamma-aminobutyric acid type A receptor determined by the volume of a second transmembrane domain residue. Mol Pharmacol. 1999;56:1087-1093.
17. Chen C, Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol. 1987;7:2745-2752.
18. Goldstein PA, Elsen FP, Ying SW, et al. Prolongation of hippocampal miniature inhibitory postsynaptic currents in mice lacking the GABA(A) receptor alpha1 subunit. J Neurophysiol. 2002;88:3208-3217.
19. Perrais D, Ropert N. Effect of zolpidem on miniature IPSCs and occupancy of postsynaptic GABAA receptors in central synapses. J Neurosci. 1999;19:578-588.
20. McKernan RM, Whiting PJ. Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci. 1996;19:139-143.
21. Pritchett DB, Sontheimer H, Shivers BD, et al. Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology. Nature. 1989;338:582-585.
22. Wieland HA, Luddens H, Seeburg PH. A single histidine in GABAA receptors is essential for benzodiazepine agonist binding. J Biol Chem. 1992;267:1426-1429.
23. Rudolph U, Crestani F, Benke D, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature. 1999;401:796-800.
24. Narahashi T, Ma J, Arakawa O, Reuveny E, Nakahiro M. GABA receptor-channel complex as a target site of mercury, copper, zinc, and lanthanides. Cell Mol Neurobiol. 1994;14:599-621.
25. Schmidt LE, Svendsen LB, Sorensen VR, Hansen BA, Larsen FS. Cerebral blood flow velocity increases during a single treatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure. Liver Transpl. 2001;7:709-712.
26. Lugaresi E, Montagna P, Tinuper P, et al. Endozepine stupor: recurring stupor linked to endozepine-4 accumulation. Brain. 1998;121:127-133.
27. Laccetti M, Manes G, Uomo G, et al. Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double blind randomized placebo controlled study. Dig Liver Dis. 2000;32:335-338.
28. Mitzner S, Loock J, Peszynski P, et al. Improvement in central nervous system functions during treatment of liver-failure with albumin dialysis MARS - a review of clinical, biochemical, and electrophysiological data. Metab Brain Dis. 2002;17:463-475.
29. Huang KW, Chao A, Chou NK, Ko WJ. Hepatic encephalopathy and cerebral blood flow improved by liver dialysis treatment. Int J Artif Organs. 2003;26:149-151.
30. Jiao Y-F, Okumiya T, Saibara T, Kudo Y, Sugiura T. Erythrocyte creatine as a marker of excessive erythrocyte destruction due to hypersplenism in patients with liver cirrhosis. Clin Biochem. 2001;34:395-398.
31. Zaki AE, Ede RJ, Davis M, Williams R. Experimental studies of blood brain barrier permeability in acute hepatic failure. Hepatology. 1984;4:359-363.